MMSI's revenue grew 8.3% year over year to $416.2M in 2026Q3 after 9.7% growth in 2026Q2, suggesting a steady top-line trajectory, while operating margin improved to 14.1% in the latest quarter.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | $1.12+7.7% vs $1.04 | $416M+1.4% vs $411M |
Q3 2026 Jul 30, 2026 | $1.19+24.1% vs $0.96 | $419M+3.4% vs $405M |
Q2 2026 Apr 30, 2026 | $0.94+11.9% vs $0.84 | $382M+1.1% vs $378M |
Q1 2026 Feb 24, 2026 | $1.04+8.3% vs $0.96 | $394M+1.0% vs $390M |
With the Fed rate decision dropping at 2:30 PM and Alphabet and Microsoft reporting before the bell, Wednesday's analyst calls on Enphase, Spotify, Whirlpool, and a newly public Rangers franchise land at a pivotal moment for markets.
The Conestoga Small Cap Composite returned -11.22% net of fees in 3Q26, trailing the -9.39% return for the Russell 2000 Growth Index. Small Cap Composite top 5 leaders include Repligen, Merit Medical, Stevanato Group, Descartes Systems and Digi International. Small Cap Composite bottom 5 laggards include Mercury Systems, AAON, RBC Bearings, SPX Technologies and UL Solutions.
Oncology stocks are gaining relevance as cancer care evolves, with Pfizer, Merit Medical Systems and Abbott advancing treatments, diagnostics and screening technologies.
SOUTH JORDAN, Utah, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2026, after the close of the stock market on Thursday, October 29, 2026. Merit plans to hold its investor conference call on the same day (Thursday, October 29, 2026) at 4:30 p.m. Eastern (3:30 p.m. Central, 2:30 p.m. Mountain, and 1:30 p.m. Pacific).
Benchmark MMSI against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Merit Medical Systems, Inc. (MMSI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $87.23 | $5.2B | 32.89 | 11.66% | 9.94% | 9.65% | — | |
| $126.56 | $4.3B | 42.23 | 7.57% | 5.68% | 6.02% | — | |
| $0.24 | $16.72M | -0.14 | 15.4% | -747.19% | -94.35% | — | |
| $58.54 | $2.98B | 195.98 | 14.88% | 2.52% | 2.93% | — | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — | |
| $19.10 | $1.41B | 7.12 | 18.52% | 43.79% | 15.84% | — |
Merit Medical Systems, Inc. (MMSI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Merit Medical Systems, Inc. (MMSI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 29, 2026·SEC
Jul 30, 2026·SEC
May 19, 2026·SEC
Get notified when MMSI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Merit Medical Systems, Inc. (MMSI) stock FAQ — growth, dividends, profitability & financials explained
Merit Medical Systems, Inc. (MMSI) reported $1.61B in revenue over the trailing twelve months. Revenue was $1.51B in fiscal year 2025. That is 2899% more than the $50.5M of fiscal year 1996.
Merit Medical Systems, Inc. (MMSI) grew revenue by 9.2% over the trailing twelve months, compared with the twelve months before.
Yes. Merit Medical Systems, Inc. (MMSI) earned $160.1M in net income over the trailing twelve months (a 9.9% net margin).
Merit Medical Systems, Inc. (MMSI) had a return on equity (ROE) of 9.7% over the trailing twelve months. That is below the market's typical 10-15%.
Merit Medical Systems, Inc. (MMSI) generated $204.2M in free cash flow over the trailing twelve months.
